Claims for Patent: 8,134,000

Summary for Patent: 8,134,000

Title:	Imidazolyl pyrimidine inhibitor compounds
Abstract:	A compound of general Formula (I) having histone deacetylase (HDAC) and/or Cyclin-dependent kinase (CDK) inhibitory activity, a pharmaceutical composition comprising the compound, and a method useful to treat diseases using the compound. ##STR00001##
Inventor(s):	Venkataramani; Chandrasekar (Redwood City, CA)
Assignee:	Gilead Sciences, Inc. (Foster City, CA)
Application Number:	12/502,870
Patent Claims:	1. A compound selected from those of Formula (I) and pharmaceutically acceptable salts thereof: ##STR00192## wherein R.sup.1, R.sup.2 and R.sup.3 are independently selected from the group consisting of H, halo, nitro, cyano, hydroxy, hydroxy(C.sub.1-10 alkyl), amino(C.sub.1-10 alkyl), haloalkyl, haloalkoxy, amino, azido, carboxyl, carbamoyl, mercapto, sulphamoyl, C.sub.1-10 alkyl, C.sub.2-10 alkenyl, C.sub.2-10 alkynyl, C.sub.1-10 alkoxy, hydroxy(C.sub.1-10 alkoxy)(C.sub.1-10 alkoxy), (C.sub.1-10 alkoxy)(C.sub.1-10 alkoxy), (C.sub.1-10 alkoxy)(C.sub.1-10 alkyl), C.sub.1-10 alkanoyl, C.sub.1-10 alkanoyloxy, N--(C.sub.1-10 alkyl)amino, N,N--(C.sub.1-10 alkyl).sub.2amino, C.sub.1-10 alkanoylamino, N--(C.sub.1-10 alkyl)carbamoyl, N,N--(C.sub.1-10 alkyl).sub.2carbamoyl, C.sub.1-10 alkyl-S(O).sub.a wherein a is 0, 1 or 2, C.sub.1-10 alkoxycarbonyl, NH.sub.2--S(O).sub.2NH--, NH.sub.2--CO--NH--, N--(C.sub.1-10 alkyl)sulphamoyl, N,N--(C.sub.1-10 alkyl).sub.2sulphamoyl, aryl, arylalkyl, aryloxy, arylthio, cycloalkyl, cycloalkylalkyl, cycloalkyloxy, heterocyclyl, heterocyclylalkyl, heterocyclyl(C.dbd.O)--, heterocyclyloxy and heterocyclylthio, wherein each R.sup.1 R.sup.2 and R.sup.3 is optionally substituted by one or more A; U.sup.1, U.sup.2, U.sup.3 and U.sup.4 are independently selected from --N--, --CH--, and --CR.sup.6--, with the proviso that at least one of U.sup.1, U.sup.2, U.sup.3 and U.sup.4 is --N--; m is 0, 1, 2, or 3; R.sup.6 is halo, hydroxy, nitro, cyano, trifluoromethyl, trifluoromethoxy, amino, carboxyl, carbamoyl, sulphamoyl, C.sub.1-10 alkyl, C.sub.2-10 alkenyl, C.sub.2-10 alkynyl, C.sub.1-10 alkoxy, C.sub.1-10 alkanoyl, N--(C.sub.1-10 alkyl)amino, N,N--(C.sub.1-10 alkyl).sub.2 amino, C.sub.1-10 alkanoylamino, N--(C.sub.1-10 alkyl)carbamoyl, N,N--(C.sub.1-10 alkyl).sub.2 carbamoyl, C.sub.1-10 alkyl-S(O).sub.a wherein a is 0, 1 or 2, NH.sub.2--S(O).sub.2NH--, N--(C.sub.1-10 alkyl)sulphamoyl or N,N--(C.sub.1-10 alkyl).sub.2sulphamoyl; wherein R.sup.6 is optionally substituted by one or more B; X is phenyl, 5-membered heteroaryl, or 6-membered heteroaryl, wherein the heteroaryl contains one or more heteroatoms selected from N, S and O; R.sup.7 represents one or more optional non-hydrogen substituents on ring X, wherein when present, each R.sup.7 is independently selected from hydroxy, halo, nitro, cyano, trifluoromethyl, trifluoromethoxy, amino, carboxyl, carbamoyl, sulphamoyl, C.sub.1-10 alkyl, C.sub.2-10 alkenyl, C.sub.2-10 alkynyl, C.sub.1-10 alkoxy, C.sub.1-10 alkanoyl, N--(C.sub.1-10 alkyl)amino, N,N--(C.sub.1-10 alkyl).sub.2 amino, C.sub.1-10 alkanoylamino, N--(C.sub.1-10 alkyl)carbamoyl, N,N--(C.sub.1-10 alkyl).sub.2 carbamoyl, C.sub.1-10 alkyl-S(O).sub.a wherein a is 0, 1 or 2, NH.sub.2--S(O).sub.2NH--, N--(C.sub.1-10 alkyl)sulphamoyl, N,N--(C.sub.1-10 alkyl).sub.2sulphamoyl, cycloalkyl, aryl and heterocyclyl; n is 0, 1, 2, 3 or 4; R.sup.8 is hydroxy, aryl or heteroaryl, wherein aryl or heteroaryl is substituted with --NH.sub.2 or --OH and aryl or heteroaryl is optionally further substituted with one or more groups selected from amino, halo, alkyl, alkenyl, alkynyl, haloalkyl, cycloalkyl, heterocyclyl, aryl, haloaryl, haloheterocyclyl, wherein alkyl, alkenyl, or alkynyl is optionally further substituted with one or more groups selected from halo, hydroxy, alkyl, haloalkyl and cycloalkyl; R.sup.9 is H, alkyl, haloalkyl, aminoalkyl, cycloalkyl, aryl, or heterocyclyl, wherein R.sup.9 is optionally substituted by one or more D; and A, B and D are independently selected from halo, nitro, cyano, hydroxy, oxo, hydroxyalkyl, haloalkyl, haloalkoxy, amino, azido, carboxyl, carbamoyl, mercapto, sulphamoyl, C.sub.1-10 alkyl, C.sub.2-10 alkenyl, C.sub.2-10 alkynyl, C.sub.1-10 alkoxy, C.sub.1-10 alkanoyl, C.sub.1-10 alkanoyloxy, N--(C.sub.1-10 alkyl)amino, N,N--(C.sub.1-10 alkyl).sub.2amino, C.sub.1-10 alkanoylamino, N--(C.sub.1-10 alkyl)carbamoyl, N,N--(C.sub.1-10 alkyl).sub.2carbamoyl, C.sub.1-10 alkyl-S(O).sub.a wherein a is 0, 1 or 2, C.sub.1-10 alkoxycarbonyl, N--(C.sub.1-10 alkyl)sulphamoyl, N,N--(C.sub.1-10 alkyl).sub.2sulphamoyl, H.sub.2NS(O).sub.2NH--, N--(C.sub.1-10 alkyl)NHS(O).sub.2NH--, N,N--(C.sub.1-10 alkyl).sub.2NS(O).sub.2NH--, aryl, aryloxy, arylthio, cycloalkyl, cycloalkyloxy, heterocyclyl, heterocyclyl(C.dbd.O)--, heterocyclyloxy and heterocyclylthio. 2. The compound of claim 1, wherein R.sup.8 is hydroxy, phenyl or 5-membered or 6-membered heteroaryl, wherein phenyl or heteroaryl is substituted with --NH.sub.2 or --OH at a ring position adjacent to attachment of the -CONH-moiety, and phenyl or heteroaryl is optionally further substituted with one or more substituents selected from amino, halo, alkyl, alkenyl, alkynyl, haloalkyl, cycloalkyl, heterocyclyl, aryl, haloaryl, haloheterocyclyl, wherein alkyl, alkenyl, or alkynyl is optionally further substituted with one or more groups selected from halo, hydroxy, alkyl, haloalkyl and cycloalkyl. 3. The compound according to claim 1, wherein U.sup.1, U.sup.2, U.sup.3 and U.sup.4 are selected to form any of the following heteroaryl moieties ##STR00193## 4. The compound of claim 1 selected from those of Formulae (I.sup.a), (I.sup.b), and (I.sup.c) and pharmaceutically acceptable salts thereof: ##STR00194## wherein U.sup.1, U.sup.2 and U.sup.3 are selected to be any of (a) U.sup.1, U.sup.2 and U.sup.3 are --CH-- or --CR.sup.6--; (b) U.sup.1 and U.sup.2 are --CH-- or --CR.sup.6-- and U.sup.3 is --N--; (c) U.sup.1 and U.sup.3 are --CH-- or --CR.sup.6-- and U.sup.2 is --N--; and (d) U.sup.1 and U.sup.2 are --N-- and U.sup.3 is --CH-- or --CR.sup.6--. 5. The compound of claim 4 selected from those of Formulae (I.sup.a-a), (I.sup.a-b), and (I.sup.a-c) and pharmaceutically acceptable salts thereof: ##STR00195## wherein R.sup.1, R.sup.2 and R.sup.3 are independently selected from the group consisting of H, halo, nitro, cyano, hydroxy, hydroxyalkyl, haloalkyl, haloalkoxy, amino, azido, carboxyl, carbamoyl, mercapto, sulphamoyl, C.sub.1-10 alkyl, C.sub.2-10 alkenyl, C.sub.2-10 alkynyl, C.sub.1-10 alkoxy, C.sub.1-10 alkanoyl, C.sub.1-10 alkanoyloxy, N--(C.sub.1-10 alkyl)amino, N,N--(C.sub.1-10 alkyl).sub.2amino, C.sub.1-10 alkanoylamino, N--(C.sub.1-10 alkyl)carbamoyl, N,N--(C.sub.1-10 alkyl).sub.2carbamoyl, C.sub.1-10 alkyl-S(O).sub.a wherein a is 0, 1 or 2, C.sub.1-10 alkoxycarbonyl, NH.sub.2--S(O).sub.2NH--, N--(C.sub.1-10 alkyl)sulphamoyl, N,N--(C.sub.1-10 alkyl).sub.2sulphamoyl, aryl, aryloxy, arylthio, cycloalkyl, cycloalkyloxy, heterocyclyl, heterocyclyl(C.dbd.O)--, heterocyclyloxy and heterocyclylthio; wherein each of R.sup.1, R.sup.2 and R.sup.3 is optionally substituted by one or more A. 6. The compound of claim 5, wherein the compound is selected from those of Formulae (I.sup.a-a), (I.sup.a-b), and (I.sup.a-c), and wherein R.sup.1, R.sup.2 and R.sup.3 are independently selected from the group consisting of H, chloro, fluoro, bromo, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, acetyl, carboxyl, methylcarboxyl, cyano, methoxymethyl, ethoxyethyl, propoxyethyl, methoxyethoxy, trifluoromethyl, hydroxyethoxy, dimethylamino, diethylamino, dimethylaminomethyl, dimethylaminoethyl, diethylaminomethyl, dimethylaminoethoxy, dimethylaminocarbonyl, dimethylaminoethylamide, trifluoromethoxymethyl, trifluoroethoxymethyl, isopropylcarbonyl, 1-hydoxyethyl, 3-oxetanoxy, trifluoroethylaminomethyl, N-methyl-N-methoxyethyl-aminoethyl, cyclopropanylmethyl, cyclobutoxy, 1-cyclopropanylethoxy, cyclopropanylmethylaminomethyl, 4-methylpiperazin-1-carbonyl, isoindolin-2-yl, N-methoxyethylcarbamoyl, N-(morpholin-4-yl)-ethylcarbamoyl, dimethylaminoethylamino, methylcarboxyl, N,N-dimethylaminoethylcarbamoyl, benzyl, phenylethyl, trifluoromethylphenylethyl, phenoxymethyl, fluorophenoxymethyl, phenylethylaminomethyl, benzylaminomethyl, triazinylmethyl, piperidinylmethyl, piperidinyloxy, trifluoromethylpiperidinylmethyl, pyridinyloxymethyl, pyridinylmethoxy, tetrahydropyrazinyloxy, methylpiperazinylmethyl, methanesulfonyl, pyrrolidin-1-yl, pyrrolidin-2-yl, pyrrolidin-3-yl, pyrrolidin-1-ylmethyl, pyrrolidin-2-ylmethyl, pyrrolidin-3-ylmethyl, pyrrolidin-1-ylethoxy, pyrrolidin-2-ylethoxy, pyrrolidin-3-ylethoxy, thiazol-4-yl, 2-methyl-thiazol-4-yl, imidazol-1-ylmethyl, imidazol-2-ylmethyl, imidazol-4-ylmethyl, imidazolidin-1-yl, imidazolidin-2-yl, imidazolidin-4-yl, imidazolidin-1-ylmethyl, imidazolidin-2-ylmethyl, imidazolidin-4-ylmethyl, imidazolin-1-yl, imidazolin-2-yl, imidazolin-4-yl, pyrazolidin-1-yl, pyrazolidin-3-yl, pyrazolidin-4-yl, pyrazolin-1-yl, pyrazolin-3-yl, pyrazolin-4-yl, piperidin-1-yl, piperidin-2-yl, piperidin-3-yl, piperidin-4-yl, piperidin-1-ylmethyl, piperidin-2-ylmethyl, piperidin-3-ylmethyl, piperidin-4-ylmethyl, piperazin-1-yl, piperazin-2-yl, piperazin-3-yl, morpholin-2-yl, morpholin-3-yl, morpholin-4-yl, morpholin-2-ylmethyl, morpholin-3-ylmethyl, morpholin-4-ylmethyl, morpholin-4-ylsulfonyl, morpholin-2-ylethoxy, morpholin-3-ylethoxy and morpholin-4-ylethoxy; R.sup.6, if present, is halo, hydroxy, alkyl or haloalkyl; m is 0, 1, or 2; n is 0, 1, or 2; R.sup.7, if present, is independently fluoro, chloro, bromo, or methyl; and R.sup.8 is hydroxy, 2-hydroxyphenyl, 2-aminophenyl, 2-amino-6-fluorophenyl, 2-amino-5-fluorophenyl, 2-amino-5-trifluoromethylphenyl, 4-aminobiphenyl-3-yl, 4'-fluoro-4-aminobiphenyl-3-yl, 2-amino-5-(thiophen-2-yl)phenyl, 5'-chloro-2-amino-5-(thiophen-2-yl)phenyl, 5'-methyl-2-amino-5-(thiophen-2-yl)phenyl, 2-amino-5-(thiophen-3-yl)phenyl, 2-aminopyridin-3-yl, 4-amino-1-phenyl-1H-pyrazol-3-yl, 2-amino-5-(3-hydroxy-3-methylbut-1-ynyl)phenyl, 2-amino-5-(4,4,4-trifluoro-3-hydroxy-3-(trifluoromethyl)but-1-ynyl)phenyl- , 2-amino-5-(3-cyclopropylprop-1-ynyl)phenyl or 2-amino-5-(3-(1-hydroxycyclopropyl)prop-1-ynyl)phenyl. 7. The compound of claim 6 which is selected from the group consisting of: N-hydroxy-4-(4-(1-isopropyl-2-methylimidazol-5-yl)pyrimidin-2-ylamino- )benzamide; N-(2-aminophenyl)-4-(4-(1-isopropyl-2-methylimidazol-5-yl)pyrimidin-2-yla- mino)benzamide; N-hydroxy-3-(4-(1-isopropyl-2-methylimidazol-5-yl)pyrimidin-2-ylamino)ben- zamide; N-(2-aminophenyl)-3-(4-(1-isopropyl-2-methylimidazol-5-yl)pyrimidi- n-2-ylamino)benzamide; N-(2-amino-5-(thiophen-2-yl)phenyl)-4-(4-(1-isopropyl-2-methylimidazol-5-- yl)pyrimidin-2-ylamino)benzamide; N-(2-amino-5-fluorophenyl)-4-(4-(1-isopropyl-2-methylimidazol-5-yl)pyrimi- din-2-ylamino)benzamide; N-(2-amino-5-(thiophen-2-yl)phenyl)-3-(4-(1-isopropyl-2-methylimidazol-5-- yl)pyrimidin-2-ylamino)benzamide; N-(2-amino-5-fluorophenyl)-3-(4-(1-isopropyl-2-methylimidazol-5-yl)pyrimi- din-2-ylamino)benzamide; N-(2-amino-5-(trifluoromethyl)phenyl)-4-(4-(1-isopropyl-2-methylimidazol-- 5-yl)pyrimidin-2-ylamino)benzamide; N-(4-amino-4'-fluorobiphenyl-3-yl)-4-(4-(1-isopropyl-2-methylimidazol-5-y- l)pyrimidin-2-ylamino)benzamide; N-(4-amino-4'-fluorobiphenyl-3-yl)-2-(4-(1-isopropyl-2-methylimidazol-5-y- l)pyrimidin-2-ylamino)thiazole-5-carboxamide; N-(2-amino-5-(thiophen-2-yl)phenyl)-2-(4-(1-isopropyl-2-methylimidazol-5-- yl)pyrimidin-2-ylamino)thiazole-5-carboxamide; N-(2-aminophenyl)-2-(4-(1-isopropyl-2-methylimidazol-5-yl)pyrimidin-2-yla- mino)thiazole-5-carboxamide; N-(2-aminophenyl)-5-(4-(1-isopropyl-2-methylimidazol-5-yl)pyrimidin-2-yla- mino)thiophene-2-carboxamide; N-hydroxy-5-(4-(1-isopropyl-2-methylimidazol-5-yl)pyrimidin-2-ylamino)thi- ophene-2-carboxamide; N-(2-amino-5-(thiophen-2-yl)phenyl)-5-(4-(1-isopropyl-2-methylimidazol-5-- yl)pyrimidin-2-ylamino)thiophene-2-carboxamide; N-(2-amino-5-fluorophenyl)-5-(4-(1-isopropyl-2-methylimidazol-5-yl)pyrimi- din-2-ylamino)thiophene-2-carboxamide; N-(4-amino-4'-fluorobiphenyl-3-yl)-5-(4-(1-isopropyl-2-methylimidazol-5-y- l)pyrimidin-2-ylamino)thiophene-2-carboxamide; N-(4-amino-4'-fluorobiphenyl-3-yl)-5-(4-(1-isopropyl-2-methylimidazol-5-y- l)pyrimidin-2-ylamino)-4-methylthiophene-2-carboxamide; N-(2-amino-5-(thiophen-2-yl)phenyl)-5-(5-fluoro-4-(1-isopropyl-2-methylim- idazol-5-yl)pyrimidin-2-ylamino)thiophene-2-carboxamide; and pharmaceutically acceptable salts thereof. 8. The compound of claim 4 selected from those of Formulae (I.sup.b-a), (I.sup.b-b), (I.sup.b-c), and (I.sup.b-d) and pharmaceutically acceptable salts thereof: ##STR00196## wherein R.sup.1, R.sup.2 and R.sup.3 are independently selected from the group consisting of H, halo, nitro, cyano, hydroxy, hydroxyalkyl, haloalkyl, haloalkoxy, amino, azido, carboxyl, carbamoyl, mercapto, sulphamoyl, C.sub.1-10 alkyl, C.sub.2-10 alkenyl, C.sub.2-10 alkynyl, C.sub.1-10 alkoxy, C.sub.1-10 alkanoyl, C.sub.1-10 alkanoyloxy, N--(C.sub.1-10 alkyl)amino, N,N--(C.sub.1-10 alkyl).sub.2amino, C.sub.1-10 alkanoylamino, N--(C.sub.1-10 alkyl)carbamoyl, N,N--(C.sub.1-10 alkyl).sub.2carbamoyl, C.sub.1-10 alkyl-S(O).sub.a wherein a is 0, 1 or 2, C.sub.1-10 alkoxycarbonyl, NH.sub.2--S(O).sub.2NH--, N--(C.sub.1-10 alkyl)sulphamoyl, N,N--(C.sub.1-10 alkyl).sub.2sulphamoyl, aryl, aryloxy, arylthio, cycloalkyl, cycloalkyloxy, heterocyclyl, heterocyclyl(C.dbd.O)--, heterocyclyloxy and heterocyclylthio; wherein each of R.sup.1, R.sup.2 and R.sup.3 is optionally substituted by one or more A. 9. The compound of claim 8 which is selected from the group consisting of: N-hydroxy-4-(4-(1-isopropyl-2-methylimidazol-5-yl)pyridin-2-ylamino)b- enzamide; N-(2-aminophenyl)-4-(4-(1-isopropyl-2-methylimidazol-5-yl)pyridi- n-2-ylamino)benzamide; N-(2-amino-5-(thiophen-2-yl)phenyl)-4-(4-(1-isopropyl-2-methylimidazol-5-- yl)pyridin-2-ylamino)benzamide; N-(2-amino-5-fluorophenyl)-4-(4-(1-isopropyl-2-methylimidazol-5-yl)pyridi- n-2-ylamino)benzamide; N-hydroxy-4-(5-(1-isopropyl-2-methylimidazol-5-yl)pyridazin-3-ylamino)ben- zamide; N-(2-aminophenyl)-4-(5-(1-isopropyl-2-methylimidazol-5-yl)pyridazi- n-3-ylamino)benzamide; N-(2-amino-5-(thiophen-2-yl)phenyl)-4-(5-(1-isopropyl-2-methylimidazol-5-- yl)pyridazin-3-ylamino)benzamide; N-(2-amino-5-fluorophenyl)-4-(5-(1-isopropyl-2-methylimidazol-5-yl)pyrida- zin-3-ylamino)benzamide; N-hydroxy-4-(4-(1-isopropyl-2-methylimidazol-5-yl)-1,3,5-triazin-2-ylamin- o)benzamide; N-(2-aminophenyl)-4-(4-(1-isopropyl-2-methylimidazol-5-yl)-1,3,5-triazin-- 2-ylamino)benzamide; N-(2-amino-5-(thiophen-2-yl)phenyl)-4-(4-(1-isopropyl-2-methylimidazol-5-- yl)-1,3,5-triazin-2-ylamino)benzamide; N-(2-amino-5-fluorophenyl)-4-(4-(1-isopropyl-2-methylimidazol-5-yl)-1,3,5- -triazin-2-ylamino)benzamide; N-(2-aminophenyl)-4-(5-(1-isopropyl-2-methylimidazol-5-yl)-1,2,4-triazin-- 3-ylamino)benzamide; N-(2-amino-5-(thiophen-2-yl)phenyl)-4-(5-(1-isopropyl-2-methylimidazol-5-- yl)-1,2,4-triazin-3-ylamino)benzamide; and pharmaceutically acceptable salts thereof. 10. The compound of claim 4 selected from those of Formulae (I.sup.c-a) and (I.sup.c-b) and pharmaceutically acceptable salts thereof: ##STR00197## wherein R.sup.9 is alkyl, haloalkyl or aminoalkyl. 11. The compound of claim 10 which is selected from the group consisting of: N-(2-aminophenyl)-4-((4-(1-isopropyl-2-methylimidazol-5-yl)pyrimidin-- 2-yl)(2,2,2-trifluoroethyl)amino)benzamide; N-hydroxy-4-((4-(1-isopropyl-2-methylimidazol-5-yl)pyrimidin-2-yl)(2,2,2-- trifluoroethyl)amino)benzamide; N-(2-aminophenyl)-4-(ethyl(4-(1-isopropyl-2-methylimidazol-5-yl)pyrimidin- -2-yl)amino)benzamide; 4-(ethyl(4-(1-isopropyl-2-methylimidazol-5-yl)pyrimidin-2-yl)amino)-N-hyd- roxybenzamide; N-(2-aminophenyl)-4-((4-(1-isopropyl-2-methylimidazol-5-yl)pyrimidin-2-yl- )(methyl)amino)benzamide; N-hydroxy-4-((4-(1-isopropyl-2-methylimidazol-5-yl)pyrimidin-2-yl)(methyl- )amino)benzamide; and pharmaceutically acceptable salts thereof. 12. A pharmaceutical composition comprising an effective amount of one or more compounds according to claim 1 and a pharmaceutically-acceptable carrier. 13. The pharmaceutical composition according to claim 12, further comprising one or more anti-cancer agents selected from the group consisting of cyclophosphamide, dacarbazine, cisplatin, methotrexate, mercaptopurine, thioguanine, fluorouracil, cytarabine, vinblastine, paclitaxel, doxorubicin, bleomycin, mitomycin, prednisone, tamoxifen, flutamide, asparaginase, rituximab, trastuzumab, imatinib, retinoic acid, colony-stimulating factor, amifostine, lenalidomide, HDAC inhibitor, CDK inhibitor, camptothecin and topotecan.

Details for Patent 8,134,000

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Recordati Rare Diseases, Inc.	ELSPAR	asparaginase	For Injection	101063	01/10/1978		2028-07-14
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	11/26/1997		2028-07-14
Idec Pharmaceuticals Corp.	RITUXAN	rituximab	Injection	103737	02/19/2002		2028-07-14
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998		2028-07-14
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017		2028-07-14
Genentech, Inc.	RITUXAN HYCELA	rituximab and hyaluronidase human	Injection	761064	06/22/2017		2028-07-14